Terns Pharmaceuticals Stock Surges on Merck's $6 Billion Acquisition Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: moomoo
Terns Pharmaceuticals shares have surged 14.1% in pre-market trading, reaching a 52-week high, following reports of Merck's plans to acquire the company for approximately $6 billion.
The acquisition discussions between Merck and Terns are in the final stages, with a potential agreement expected soon. This news has significantly boosted investor interest and market confidence in Terns, reflecting the strategic value of the deal.
The implications of this acquisition could be substantial for Terns, enhancing its market position and providing additional resources for its ongoing research and development efforts, particularly in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
